21:33 , Sep 26, 2018 |  BC Extra  |  Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
19:07 , Dec 15, 2017 |  BC Week In Review  |  Company News

Federal Appeals Court rules that Biosimilars Act preempts state law

In a ruling issued in the case of Amgen Inc. v. Sandoz Inc. concerning biosimilars, the U.S. Court of Appeals for the Federal Circuit (CAFC) held that the federal Biologics Price Competition and Innovation Act...
20:40 , Dec 14, 2017 |  BC Extra  |  Politics & Policy

Appeals court: Federal biosimilars act preempts state law

In a ruling issued in the case of Amgen Inc. v. Sandoz Inc. concerning biosimilars, the U.S. Court of Appeals for the Federal Circuit (CAFC) held that the federal Biologics Price Competition and Innovation Act...
18:48 , Sep 22, 2017 |  BioCentury  |  Politics, Policy & Law

Conferred immunity in IPR

The outcome of Allergan plc ’s gambit to shield its Restasis cyclosporine patents from inter partes review could determine the fate of the IPR system and upset the balance of power between generic and brand...
22:24 , Sep 15, 2017 |  BC Extra  |  Politics & Policy

U.S. government asserts biosimilars act preempts state law

On Monday, the U.S. government submitted an amicus brief to the U.S. Court of Appeals for the Federal Circuit (CAFC) in the case of Amgen Inc. v. Sandoz Inc. arguing that the federal Biologics Price...
20:52 , Jun 16, 2017 |  BC Week In Review  |  Company News

SCOTUS shortens time to market for Novartis' biosimilar of Neupogen from Amgen

A unanimous ruling issued June 12 by the U.S. Supreme Court will shorten the timeline for biosimilars to reach the market by six months, and is likely to give the drugs' manufacturers flexibility to decline...
21:58 , Jun 12, 2017 |  BC Extra  |  Politics & Policy

SCOTUS speeds biosimilars to market

A unanimous ruling issued Monday by the U.S. Supreme Court will shorten the timeline for biosimilars to reach the market by six months, and is likely to give the drugs' manufacturers flexibility to decline to...
23:02 , Apr 26, 2017 |  BC Extra  |  Politics & Policy

Supreme Court doesn't tip hand on biosimilars case

The Supreme Court did not show a clear preference for either party during oral arguments Wednesday in litigation between Amgen Inc. (NASDAQ:AMGN) and the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). The case centers on...
04:31 , Apr 22, 2017 |  BioCentury  |  Politics, Policy & Law

Shall we dance?

The U.S. Supreme Court will hear oral arguments Wednesday in a case that could determine how quickly biosimilars can launch after approval -- by clarifying the ground rules for when and how patent disputes are...
07:00 , Sep 5, 2016 |  BioCentury  |  Finance

Medivation elation

Deep analysis and market timing converged to make Medivation Inc. (NASDAQ:MDVN) one of the biggest-ever biotech wins for Bain Capital Public Equity. The firm, which has been enjoying trading gains on the stock for the...